The Association Between Obesity and the 5-Year Prevalence of Morbidity and Mortality Among Adults with Type 2 Diabetes

被引:5
作者
Boye, Kristina S. [1 ]
Ford, Janet H. [1 ]
Thieu, Vivian T. [2 ]
Lage, Maureen J. [3 ]
Terrell, Kendra A. [1 ]
机构
[1] Eli Lilly & Co, Lilly Corp Ctr, Value Evidence & Outcomes Dept, 893 Delaware St, Indianapolis, IN 46225 USA
[2] Eli Lilly & Co, Lilly Corp Ctr, Med Affairs, Diabet, 893 Delaware St, Indianapolis, IN 46225 USA
[3] HealthMetr Outcomes Res, 17 Bentons Knoll, Guilford, CT 06437 USA
关键词
Complications; Morbidity; Mortality; Obesity; Prevalence; Type; 2; diabetes; CARDIOVASCULAR-DISEASE; METABOLIC SYNDROME; EPIDEMIOLOGY; MELLITUS;
D O I
10.1007/s13300-023-01384-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IntroductionThis retrospective claims database study examined the prevalence of mortality and morbidity among adults with type 2 diabetes (T2D) and obesity.MethodsThe study used deidentified data from 2007 to 2021 from the Optum (R) Market Clarity Dataset. A cohort of adults with T2D and obesity were identified, and age- and sex-adjusted prevalence rates were calculated for mortality, a composite cardiovascular outcome (CCO), a composite microvascular outcome (CMO), and other complications. Results were examined overall and by obesity class (class 1, class 2, and class 3).ResultsFor the 15,970 adults included in the study, the prevalence of CCO and CMO after 5 years was 15.3% and 60.7%, respectively. The 5-year prevalence of mortality was 10.9%. There were statistically significant differences in prevalence rates by obesity class, with obesity class 3 associated with higher rates of morbidity and mortality compared to obesity classes 1 or 2. Specifically, after 5 years, the prevalence of mortality was 9.4%, 10.3% and 13.6% for obese classes 1, 2 and 3, respectively (P < 0.05 between class 3 and class 2 or 1). Similarly, For obesity classes 1, 2 and 3, the 5-year prevalence of CCO was 13.0%, 14.5% and 18.4% and the rates for CMO were 58.0%, 57.9% and 64.8%, respectively (both P < 0.05 between class 3 and class 2 or 1). Regarding other complications, differences in the prevalence of atherosclerotic cardiovascular disease (ASCVD) and obstructive sleep apnea (OSA) were statistically significantly higher with increasing obesity class.ConclusionsThe results indicate that for a cohort of adults with T2D and obesity, obesity class 3 is associated with significantly higher mortality and morbidity, including CCO, CMO, ASCVD and OSA. These findings suggest that treatment which reduces obesity among individuals with T2D may have significant health benefits, although additional studies are needed to confirm the results.
引用
收藏
页码:709 / 721
页数:13
相关论文
共 41 条
  • [1] Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?
    Abdul-Ghani, Muhammad
    DeFronzo, Ralph A.
    Del Prato, Stefano
    Chilton, Robert
    Singh, Rajvir
    Ryder, Robert E. J.
    [J]. DIABETES CARE, 2017, 40 (07) : 813 - 820
  • [2] Health Effects of Overweight and Obesity in 195 Countries over 25 Years
    Afshin, Ashkan
    Forouzanfar, Mohammad H.
    Reitsma, Marissa B.
    Sur, Patrick
    Estep, Kara
    Lee, Alex
    Marczak, Laurie
    Mokdad, Ali H.
    Moradi-Lakeh, Maziar
    Naghavi, Mohsen
    Salama, Joseph S.
    Vos, Theo
    Abate, Kalkidan H.
    Abbafati, Cristiana
    Ahmed, Muktar B.
    Al-Aly, Ziyad
    Alkerwi, Ala'a
    Al-Raddadi, Rajaa
    Amare, Azmeraw T.
    Amberbir, Alemayehu
    Amegah, Adeladza K.
    Amini, Erfan
    Amrock, Stephen M.
    Anjana, Ranjit M.
    Arnlov, Johan
    Asayesh, Hamid
    Banerjee, Amitava
    Barac, Aleksandra
    Baye, Estifanos
    Bennett, Derrick A.
    Beyene, Addisu S.
    Biadgilign, Sibhatu
    Biryukov, Stan
    Bjertness, Espen
    Boneya, Dube J.
    Campos-Nonato, Ismael
    Carrero, Juan J.
    Cecilio, Pedro
    Cercy, Kelly
    Ciobanu, Liliana G.
    Cornaby, Leslie
    Damtew, Solomon A.
    Dandona, Lalit
    Dandona, Rakhi
    Dharmaratne, Samath D.
    Duncan, Bruce B.
    Eshrati, Babak
    Esteghamati, Alireza
    Feigin, Valery L.
    Fernandes, Joao C.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (01) : 13 - 27
  • [3] American Diabetes Association, 1995, UND A1C DIAGN
  • [4] [Anonymous], 2021, Nonalcoholic fatty liver disease
  • [5] Ashraf M Javed, 2013, Mo Med, V110, P499
  • [6] Epidemiology of Obesity and Diabetes and Their Cardiovascular Complications
    Bhupathiraju, Shilpa N.
    Hu, Frank B.
    [J]. CIRCULATION RESEARCH, 2016, 118 (11) : 1723 - 1735
  • [7] Trends in HbA1c and Body Mass Index Among Individuals with Type 2 Diabetes: Evidence from a US Database 2012-2019
    Boye, Kristina S.
    Lage, Maureen J.
    Shinde, Shraddha
    Thieu, Vivian
    Bae, Jay Patrick
    [J]. DIABETES THERAPY, 2021, 12 (07) : 2077 - 2087
  • [8] Healthcare outcomes for patients with type 2 diabetes with and without comorbid obesity
    Boye, Kristina S.
    Lage, Maureen J.
    Terrell, Kendra
    [J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2020, 34 (12)
  • [9] Central Obesity is Associated With Neuropathy in the Severely Obese
    Callaghan, Brian C.
    Reynolds, Evan
    Banerjee, Mousumi
    Chant, Ericka
    Villegas-Umana, Emily
    Feldman, Eva L.
    [J]. MAYO CLINIC PROCEEDINGS, 2020, 95 (07) : 1342 - 1353
  • [10] Direct medical costs of obesity in the United States and the most populous states
    Cawley, John
    Biener, Adam
    Meyerhoefer, Chad
    Ding, Yuchen
    Zvenyach, Tracy
    Smolarz, B. Gabriel
    Ramasamy, Abhilasha
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (03) : 354 - 366